RedHill Bio doses first COVID-19 patient with Opaganib in Israel; shares up 9% premarket
- RedHill Biopharma (NASDAQ:RDHL) has dosed the first patient with COVID-19 infection with its IND, opaganib (Yeliva, ABC294640), in Israel.
- The treatment is administered under a compassionate use program in accordance with the Israeli Ministry of Health guidelines, with additional patients expected to be treated in coming days.
- RedHill is also preparing for potential ramp-up of manufacturing of opaganib.
- Shares are up 9% premarket.